Kairos Therapeutics is developing a pipeline of antibody-drug conjugate (ADC) therapeutics for the treatment of various forms of cancer. The technology was developed in-house at The Centre for Drug Research and Development (CDRD) and has been exclusively licensed to Kairos from CDRD through its commercialization vehicle, CDRD Ventures Inc.